Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Selective Retinal Pigment Epithelium Laser Therapy (SRT) for Macular Disease of the Retina

NCT02088151 is registered in ClinicalTrials.gov with Insel Gruppe AG, University Hospital Bern as lead sponsor.

NCT NCT02088151
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02088151 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Selective Retinal Pigment Epithelium Laser Therapy (SRT) for Macular Disease of the Retina
Lead sponsor
Insel Gruppe AG, University Hospital Bern
Phase
Not applicable
Overall status
Terminated
Start date
June 30, 2010
Completion date
February 1, 2022
Enrollment
18 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

age-related macular degeneration, central serous chorioretinopathy, macular edema, retinal neovascularization, retinal vein occlusion